AbbVie Inc. said it's working on a drug that will treat and prevent Covid-19.

The North Chicago drug maker (NYSE: ABBV) said it's working with a Dutch university and a Dutch medical center, as well as a Massachusetts biopharmaceutical company, to develop a novel antibody therapeutic for Covid-19.

AbbVie said its partners are the Utrecht University (UU) and Erasmus Medical Center (EMC) of The Netherlands, and Harbour BioMed. AbbVie said it will support the three entities, which discovered a neutralizing Covid-19 antibody, through the preclinical activities, and prepare for later stage preclinical and clinical development work.

“Treatment and prevention of Covid-19 remains a critical global need. The antibody discovered by UU, EMC and Harbour BioMed is extremely promising based on the mechanism by which it targets the virus and on its developability as a fully human protein. We look forward to working with this outstanding team to advance this antibody towards clinical trials," said Dr. Tom Hudson, senior vice president, research and development and chief scientific officer of AbbVie, in a statement.

Right now, there isn't a treatment for Covid-19.

Last month, AbbVie said it's in the second clinical trial phase of its Imbruvica (ibrutinib) drug to treat patients with moderate to severe Covid-19. The company also said it's supporting Covid-19 clinical research by working with health authorities and institutions around the world to determine the efficiency and safety of its Kaletra/Aluvia therapy for the treatment of HIV, against Covid-19.